| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| February 25, 2020 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 155,000 | $1.16 | 187,700 | |
| May 30, 2017 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 176,429 | -- | 176,429 | |
| July 18, 2022 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 177,000 | -- | 177,000 | |
| February 25, 2011 | CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 180,000 | $2.49 | 845,000 | |
| February 20, 2015 | Ten Percent Owner | Form 4 | Open market or private sale of non-derivative or derivative security | 199,765 | $3.30 | 2,512,423 | |
| May 6, 2013 | CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 200,000 | -- | 1,165,000 | |
| January 16, 2006 | VP of Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 200,000 | -- | 200,000 | |
| June 9, 2004 | President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 200,000 | -- | 1,950,000 | |
| June 9, 2004 | Vice President,General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 200,000 | -- | 200,000 | |
| June 15, 2020 | CFO | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 250,000 | -- | 189,951 | |
| June 15, 2020 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 439,951 | |
| May 15, 2018 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 305,047 | |
| May 15, 2018 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 304,951 | |
| March 19, 2021 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 714,951 | |
| June 9, 2004 | Senior Vice President | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 400,000 | -- | 400,000 | |
| January 3, 2007 | President, CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 430,000 | $2.42 | 430,000 | |
| March 19, 2021 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 650,000 | -- | 1,996,071 | |
| June 15, 2020 | Director, Chairman, President and CEO | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 850,000 | -- | 510,071 | |
| June 15, 2020 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 850,000 | -- | 1,346,071 | |
| May 15, 2018 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 850,000 | -- | 1,046,071 | |
| June 7, 2005 | Director, President and CEO | Form 4 | Bona fide gift | 995,500 | -- | 5,282,676 | |
| June 1, 2005 | Director, President and CEO | Form 4 | Bona fide gift | 1,000,000 | -- | 4,287,176 | |
| May 17, 2004 | Director, President and CEO | Form 4 | Bona fide gift | 1,000,000 | -- | 3,537,176 | |
| July 29, 2005 | President, CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,440,000 | -- | 6,440,000 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
